Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 139

Sort by

Sort Order Select

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Gvhd Therapy with Ruxolitinib Is Frequently Associated with Cytopenias, but Significant Decline in Hemoglobin Level Was Only Observed in Non-Responders at Day 28

Stephanie Gergoudis, Sean M. Devlin, Pamela Susman, Amandeep Singh, Stephanie Chinapen, Miguel Angel Perales, Doris M. Ponce

Blood (2024) 144 (Supplement 1): 7349.

https://doi.org/10.1182/blood-2024-210081

Published: 2024

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Charlotte FM Hughes, Andrew Lin, Maria Bromberg, Sean M. Devlin, Amethyst Saldia, Danielle E Engstler, Danielle M Hanley, Yetunde Aremu, Martin Donach, Elizabeth Hoover, Oscar B Lahoud, Arnab Ghosh, Moneeza Walji, Miguel-Angel Perales, Michael Scordo, Sergio A. Giralt, Gunjan L. Shah, Parastoo B Dahi

Blood (2024) 144 (Supplement 1): 6492.

https://doi.org/10.1182/blood-2024-208310

Published: 2024

Journal Articles

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Yannis K. Valtis, David Nemirovsky, Sean M. Devlin, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Anjali S. Advani, Marlise R. Luskin, Evan C. Chen, Omer Jamy, Michael R. Grunwald, Ibrahim Muhsen, Noam E. Kopmar, Bhagirathbhai Dholaria, Simone E. Dekker, Jessica T. Leonard, George Yaghmour, Stephanie B. Tsai, Wendy Stock, Jozal Moore, Kristen M. O'Dwyer, Aaron C. Logan, Matthew P Connor, Noelle Frey, Evandro Bezerra, Sumithira Vasu, Kaitlyn C Dykes, Minoo Battiwalla, Chenyu Lin, Matthew Ulrickson, Ran Reshef, Ryan D. Cassaday, Laquisha C. Hill, Catherine J. Lee, Vamsi K. Kota, Jacob Boccucci, Joshua Sasine, Akil Merchant, Vinod Pullarkat, Amelia Langston, Talal Hilal, Rawan Faramand, Melhem M. Solh, Tamer Othman, Timothy E O'Connor, Navneet Majhail, Shabaz Malik, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Muthu V. Kumaran, Marc Schwartz, Veronika Bachanova, Sean I. Tracy, Maria Odstrcil Bobillo, Abdullah Ladha, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Michael Daunov, John Mathews, Paul Shaughnessy, Bijal D Shah, Lori Muffly, Jae H. Park

Blood (2024) 144 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2024-201610

Published: 2024

Journal Articles

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2024-208094

Published: 2024

Journal Articles

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Blood (2024) 144 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2024-212274

Published: 2024

Journal Articles

Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia

Sanam Shahid, Serena Mathew, Sydney Souness, Erin R. Burns, Jasmine S. Um, Sarah Yoo, Winson Cai, Mary Ann Pohl, Takeshi Fujino, Pu Zhang, Jennifer Lewis, Sean M. Devlin, Ivo Lorenz, Renier Brentjens, Anthony F. Daniyan

Blood (2024) 144 (Supplement 1): 3406.

https://doi.org/10.1182/blood-2024-194391

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts

Armel L. Batchi-Bouyou, Duc Tran, Michael Raddatz, Teng Gao, Caitlyn Vlasschaert, Brian Sharber, Jie Liu, Giulia Petrone, Irenaeus C.C. Chan, J. Scott Beeler, Griffen Mustion, Sean M. Devlin, Alexander G. Bick, Kelly Bolton

Blood (2024) 144 (Supplement 1): 1285.

https://doi.org/10.1182/blood-2024-210900

Published: 2024

Journal Articles

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Blood (2024) 144 (Supplement 1): 2369.

https://doi.org/10.1182/blood-2024-201029

Published: 2024

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2024-208490

Published: 2024

Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Blood (2024) 144 (4): 359–367.

https://doi.org/10.1182/blood.2024024371

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Blood (2023) 142 (Supplement 1): 357.

https://doi.org/10.1182/blood-2023-174728

Published: 2023

Journal Articles

Analysis of 3,843 Unrelated Donors (URD) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Major Implications for Transplant Center & Registry Operations

Warren B Fingrut, Eric Davis, Anne Archer, Samantha Brown, Sean M. Devlin, Melissa Nhaissi, Candice Rapoport, Stephanie Chinapen, Amanda Kelly, Deborah Wells, Andromachi Scaradavou, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Ioannis Politikos, Brian C. Shaffer, Juliet N Barker

Blood (2023) 142 (Supplement 1): 5114.

https://doi.org/10.1182/blood-2023-180439

Published: 2023

Journal Articles

Gender Disparities in Allograft Access Due to HLA-Sensitization in Multiparous Women: Implications for Evaluation of Female Patients for Alternative Donor Transplantation

Warren B Fingrut, Eric Davis, Anne Archer, Samantha Brown, Sean M. Devlin, Stephanie Chinapen, Andromachi Scaradavou, Ioannis Politikos, Amanda Blouin, Brian C. Shaffer, Juliet N Barker

Blood (2023) 142 (Supplement 1): 3759.

https://doi.org/10.1182/blood-2023-180416

Published: 2023

Journal Articles

Successful Incorporation of Electronic Patient Reported Outcomes Using Promis-29 into Standard of Care after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy

Gunjan L. Shah, Stephanie Lobaugh, Ranjit Sukhu, Sean M. Devlin, Thomas Atkinson, Elizabeth Kemeny, Peter Stetson, Miguel-Angel Perales, Sergio A. Giralt, Michael Scordo

Blood (2023) 142 (Supplement 1): 7382.

https://doi.org/10.1182/blood-2023-179330

Published: 2023

Journal Articles

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

Giulio Cassanello, Efrat Luttwak, Sean M. Devlin, Alejandro Luna De Abia, Magdalena Corona, Ivan Landego, Allison Parascondola, Amethyst Saldia, Ana Alarcon Tomas, Parastoo B. Dahi, Richard J. Lin, M. Lia Palomba, Jae H. Park, Gilles Salles, Miguel-Angel Perales, Michael Scordo, Roni Shouval, Gunjan L. Shah

Blood (2023) 142 (Supplement 1): 6898.

https://doi.org/10.1182/blood-2023-190500

Published: 2023

Journal Articles

CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2023-190326

Published: 2023

NARROW

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Gvhd Therapy with Ruxolitinib Is Frequently Associated with Cytopenias, but Significant Decline in Hemoglobin Level Was Only Observed in Non-Responders at Day 28

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Developing an Optimal Fully-Human CD371-Targeting IL-18 Secreting CAR T Cell for the Treatment of Acute Myeloid Leukemia

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Predictive Modeling of Clonal Hematopoiesis across Diverse Cohorts

When Can We Define Cure after CAR-T Therapy in LBCL? Insights from Serial Landmark Analyses

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

A Phase II Trial of Prophylactic Anakinra to Prevent Neurotoxicity in Patients Receiving Anti-CD19 CAR T-Cell Therapy for Relapsed or Refractory Lymphoma: Final Results from Cohort 2

Analysis of 3,843 Unrelated Donors (URD) for 455 Allograft Candidates Reveals Low URD Availability with Marked Racial/ Ethnic Disparities: Major Implications for Transplant Center & Registry Operations

Gender Disparities in Allograft Access Due to HLA-Sensitization in Multiparous Women: Implications for Evaluation of Female Patients for Alternative Donor Transplantation

Successful Incorporation of Electronic Patient Reported Outcomes Using Promis-29 into Standard of Care after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy

Evaluation of the Impact of Tocilizumab Use in Recipients of CAR T Cells for Non-Hodgkin Lymphoma

CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only